Yokoyama O, Ishiura Y, Nakamura Y, Ohkawa M
Department of Urology, School of Medicine, Kanazawa University.
Hinyokika Kiyo. 1995 Jul;41(7):521-4.
Nine patients with persistent urinary incontinence due to neurogenic bladder and intolerable systemic side effects on oral anticholinergic agents were treated with intravesical instillation of oxybutynin hydrochloride. Two tablets (6 mg) dissolved in 10 ml of physiological saline or sterile water were instilled into the bladder two times daily via self intermittent catheterization. The mean bladder capacity increased from 128 to 212 ml 1 month after intravesical instillation of oxybutynin hydrochloride, although this difference was not significant. The bladder was augmented more efficaciously in patients with overactive detrusor than patients with an underactive detrusor. Subjective improvement was recognized in 4 patients. Among 5 patients who discontinued therapy due to ineffective results, maximum urethral closure pressure below 50 cmH2O was seen in 4. Intravesical instillation of oxybutynin hydrochloride was considered to be ineffective clinically in patients with underactive detrusor and low urethral closure pressure. Although no systemic side effects were observed, a decrease of bladder capacity was recognized in 2 patients.
9例因神经源性膀胱导致持续性尿失禁且口服抗胆碱能药物出现难以耐受的全身副作用的患者,接受了膀胱内灌注盐酸奥昔布宁治疗。将两片(6毫克)药物溶解于10毫升生理盐水中或无菌水中,通过自我间歇性导尿术,每天向膀胱内灌注两次。膀胱内灌注盐酸奥昔布宁1个月后,平均膀胱容量从128毫升增加到212毫升,尽管这一差异并不显著。与逼尿肌活动低下的患者相比,逼尿肌活动亢进的患者膀胱容量增加更为有效。4例患者有主观改善。在因治疗无效而停药的5例患者中,4例患者的最大尿道闭合压低于50厘米水柱。对于逼尿肌活动低下且尿道闭合压低的患者,膀胱内灌注盐酸奥昔布宁在临床上被认为无效。尽管未观察到全身副作用,但有2例患者出现膀胱容量减少。